

Claim Amendments

Claims 1-20 (canceled)

Claim 21 (currently amended): A method for treating cancer cells in a patient comprising the steps of:

introducing an increased level of labeled ~~AFP-receptor~~ antibodies against alphafetoprotein in relation to normal non-malignant individuals into ~~to cancer cells in the~~ patient; and

reacting the ~~AFP-receptor~~ labeled antibodies against alphafetoprotein with the ~~AFP~~ alphafetoprotein receptor or alphafetoprotein receptor binding sites on the alphafetoprotein receptor for the labeled antibody of the cancer cells from the group consisting of ovary, uterus, rectum, brain, liver, blood, serum and bone of the patient to inhibit growth of the cancer cells or kill the cancer cells.

Claim 22 (currently amended): A method as described in Claim 21 wherein the introducing step includes the step of injecting the ~~AFP-receptor~~ labeled antibodies into the patient.

Claim 23 (currently amended): A method as described in Claim 22 wherein the injecting step includes the step of injecting through an IV into the patient's blood stream the ~~AFP-receptor~~ labeled antibodies.

Claim 24 (currently amended): A method as described in Claim 22 wherein the injecting step includes the step of injecting the ~~AFP-receptor~~ labeled antibodies into the patient at a location in proximity to the cancer cells.

Claims 25 and 26 (canceled)

Claim 27 (currently amended): A method as described in Claim 21 wherein the reacting step includes the step of reacting ~~AFP~~ alphafetoprotein receptor of cancer cells of the patient with ~~AFP-receptor~~ the labeled antibodies so the ~~AFP~~ alphafetoprotein receptor of the cancer cells are blocked or functionally impaired.

Claim 28 (currently amended): A method as described in Claim 21 wherein the ~~AFP-receptor~~ labeled antibodies are ~~AFP-receptor~~ labeled antibodies which fix complement, and wherein the reacting step includes the step of reacting the ~~AFP-receptor~~ labeled antibodies which fix complement to the cancer cell so when complement chain reaction occurs, holes are punctured into the cancer cell's membrane which kill the cancer cell.

Claim 29 (currently amended): A method as described in Claim 21 wherein the ~~AFP-receptor~~ labeled antibodies are conjugated to drugs or toxins, and wherein the reacting step includes the step of reacting the ~~AFP-receptor~~ labeled antibodies conjugated with drugs or toxins to the cancer cell so the cancer cells engulf the drugs or toxins into the cancer cells where enzymes of the cancer cells cut the drugs or toxins free from the antibodies causing the cell to be irreversibly damaged and killed.

Claim 30 (currently amended): A method as described in Claim 21 wherein the ~~AFP-receptor~~ labeled antibodies are radiolabelled, and the reacting step includes the step of reacting the radiolabelled ~~AFP-receptor~~ antibodies with cancer cells in the patient so radiation from the radiolabelled ~~AFP-receptor~~ antibodies at a short distance from the cancer cell's DNA damages the DNA thus inducing death in the cancer cells.

Claim 31 (original): A method as described in Claim 21 wherein the antibodies are monoclonal antibodies, polyclonal antibodies, antibodies from a species different than the patient, or antibodies produced in-vitro from lymphocytes of the same species as the patient.

Claims 32-39 (canceled)